Madrigal Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	958.4	180.13	-	-	-
Revenue Growth (YoY)	432.05%	-	-	-	-
Cost of Revenue	56.15	6.23	-	-	-
Gross Profit	902.26	173.9	-	-	-
Selling, General & Admin	813.83	435.06	108.15	48.13	37.32
Research & Development	388.53	236.72	272.35	245.44	205.16
Total Operating Expenses	1,202	671.78	380.5	293.57	242.48
Operating Income	-300.1	-497.88	-380.5	-293.57	-242.48
Interest Income	37.36	46.65	19.58	2.19	0.36
Interest Expense	-22.31	-14.67	-12.71	-3.96	-
Other Non-Operating Income (Expense)	-3.24	-	-	-	0.27
Total Non-Operating Income (Expense)	11.81	31.98	6.87	-1.78	0.64
Pretax Income	-288.28	-465.89	-373.63	-295.35	-241.85
Net Income	-288.28	-465.89	-373.63	-295.35	-241.85
Net Income to Common	-288.28	-465.89	-373.63	-295.35	-241.85
Shares Outstanding (Basic)	22	21	19	17	17
Shares Outstanding (Diluted)	22	21	19	17	17
Shares Change (YoY)	5.46%	13.83%	9.05%	3.64%	7.05%
EPS (Basic)	-12.85	-21.90	-19.99	-17.23	-14.63
EPS (Diluted)	-12.85	-21.90	-19.99	-17.23	-14.63
Free Cash Flow	-190.02	-457.03	-325.71	-225.07	-184.13
Free Cash Flow Per Share	-8.47	-21.48	-17.43	-13.13	-11.14
Gross Margin	94.14%	96.54%	-	-	-
Operating Margin	-31.31%	-276.39%	-	-	-
Profit Margin	-30.08%	-258.64%	-	-	-
FCF Margin	-19.83%	-253.72%	-	-	-
EBITDA	-298.59	-496.78	-379.97	-293.1	-242.08
EBITDA Margin	-31.16%	-275.78%	-	-	-
EBIT	-300.1	-497.88	-380.5	-293.57	-242.48
EBIT Margin	-31.31%	-276.39%	-	-	-

Updated Feb 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q